LexDanaLexDanabeta
Inventor

Henrik Clausen

Inventor
Holte, DK

Overview

64→
Patents
1989–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 64 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary
C12NMicroorganisms or enzymes17%
A61KPreparations for medical, dental or toiletry purposes17%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations16%
C07KPeptides15%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture3%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
C12YEnzymes3%
LOC213%
Y02ATechnologies for adaptation to climate change3%
PatentTitleYear
11,067,578Tn-MUC4 binding polypeptides and uses thereof202110,919,973Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies202110,889,845Production of N-glycoproteins for enzyme assisted glycomodification202110,858,671N-glycosylation202010,139,414Tn-MUC4 binding polypeptides and uses thereof201810,017,576Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies20189,588,121'Method for early detection of cancer'20179,359,436'Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies'20169,034,626'Methods of preparing tissues for xenotransplantation using alpha-galactosidases'20159,029,331'Glycopegylated granulocyte colony stimulating factor'20159,024,110'Methods for glyco-engineering plant cells for controlled human O-glycosylation'20158,912,311'Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies'20148,883,478'Methods of preparing tissues for xenotransplantation using α-galactosidases'20148,697,411'Streptomyces griseoplanus comprising an α-galactosidase for removing immunodominant α-galactose monosaccharides from blood group B or AB reactive cells'20148,517,967'Methods of using an apparatus for prolonging survival of platelets using CMP-sialic acid, UDP-galactose or both'20138,440,798'Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies'20138,361,961'O-linked glycosylation of peptides'20138,268,967'Glycopegylated interferon α'20128,221,745'Prolonging survival of platelets using CMP-sialic acid,UDP-galactose or both'20128,052,667'Apparatus for prolonging survival of platelets'20117,993,896'Streptomyces griseoplanus α-galactosidases for removing immunodominant α-galactose monosaccharides from blood group B or AB reactive cells'2011D0641054'Element of a construction set toy'20117,951,552'Method of preparing non-human tissues for xenotransplantation using α-galactosidase'20117,932,364'Compositions and methods for the preparation of human growth hormone glycosylation mutants'2011D0630272'Track element'2011D0630270'Track element'2011D0630271'Track'20117,858,295'Methods for prolonging survival of platelets using UDP-galactose'20107,771,978'β1,4mannosyltransferases'20107,767,415'Compositions and methods for modifying blood cell carbohydrates'2010D0614247'Element of a construction set'20107,670,816'UDP-galactose:β-D-galactose-R 4-α-D-galactosyltransferase, α4gal-T1'20107,476,527'UDP-galactose:β-N-acetyl-glucosamine β-1,3-galactosyl transferases, β-3Gal-T5'20097,449,316'UDP-galactose: β-D-galactose-R 4-α-D-galactosyltransferase, α4Gal-T1'20087,381,554'UDP-N-acetylglucosamine: galactose-β1,3-N-acetylgalactosamine-α-R/N-acetylglucosamine-β1,3-N-acetylgalactosamine-α-R (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2/4GnT'20087,374,919'UDP-galactose: β-N-acetyl-glucosamine β-1,4-galactosyltransferase, β4Gal-T2'20087,338,932'Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments'20087,338,933'O-linked glycosylation of peptides'20087,332,279'UDP-galactose: β-N-acetyl-glucosamine β1,3 galactosyltransferases, β3gal-T5'20087,241,282'Compositions and methods for prolonging survival of platelets'20077,115,404'UDP-galactose: β-D-galactose-R 4-α-D-galac-tosyltransferase, α4Gal-T1'20067,097,994'UDP-N-acetylglucosamine:galactose-β1,3-N-acetylgalactosamine-α-R/ (GlcNAc to GaINAc) β1-6 N-acetylglucosaminyltransferase, C2GnT3'20067,094,887'UDP-N-acetylglucosamine: galactose-β1,3-N-acetylgalactosamine-α-R(GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2GnT3'20067,078,206'UDP-N-acetylglucosamine: galactose-β1,3-N-acetylgalactosamine-α-R/ (GlcNAc to GalNAc) β1,6N-acetylglucosaminyltransferase, C2GnT3'20066,995,004'UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β 1,3-N-ACETYLGALACTOSAMINE-α-R / N-ACETYLGLUCOSAMINE-β 1,3,-N-ACETYLGALACTOSAMINE-α-R (GLCNAC TO GALNAC) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2/4GNT'20066,916,649'UDP-galactose: β-N-acetyl-glucosamine β-1,4-galactosyltransferase, β4Gal-T2'20056,800,468'UDP-galactose: -N-acetyl-glucosamine 1,3galactosyltransferases, 3Gal-T5'20046,794,169'UDP-N-acetylglucosamine: galactose-1,3-N-acetylgalactosamine--R / (GlcNAc to GalNAc) 1,6-N-acetylglucosaminyltransferase, C2GnT3'20046,635,461'UDP-N-acetylglucosamine: galactose-1, 3-N-acetylgalactosamine--R/(GlcNAc to GalNAc) 1,6-N-acetylglucosaminyltransferase, C2GnT3'20036,558,934'UDP-galactose: -N-acetyl-glucosamine -1,4-galactosyl-transferase, 4Gal-T2'20036,465,220'Glycosylation using GalNac-T4 transferase'20025,876,716'Method of using an antibody to the TN antigen for the inhibition of HIV infection'19995,871,990'UDP-N-acetyl-.alpha.-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase, gAlnAc-T3'1999D0395681'Toy building element'19985,747,048'Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates'19985,660,834'Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates'19975,421,733'Synthesis of Le.sup.x ; dimeric Le.sup.x (difucosyl Y.sub.2 ; III.sup.3 FucV.sup.3 FucnLc.sub.6 Cer); sialylated forms thereof; and analogues thereof'19955,418,129'Blood treatment method'19955,326,857'ABO genotyping'19945,240,833'Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides'19935,229,289'Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates'19935,068,191'Purified histo-blood group A glycosyltransferase and antibodies thereto'19914,942,224'A-associated H-antigens, monoclonal antibodies specific thereto and methods for employing the same in blood typing'19904,857,639'A-associated H-antigens, monoclonal antibodies specific thereto and methods for employing the same in blood typing'1989

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1989–1998Patents assigned to BIOMEMBRANE INST (10)· patent assignee history
1989–1998Based in Seattle, WA, US· patent location history
1994–2021Based in Holte, DK· patent location history
2002–2009Patents assigned to GLYCOZYM APS (15)· patent assignee history
2008Based in Hoite, DK· patent location history
2010–2017Patents assigned to CLAUSEN HENRIK (11)· patent assignee history
2010–2015Patents assigned to VELICO MEDICAL INC (9)· patent assignee history
2010–2011Patents assigned to LEGO AS (5)· patent assignee history
2010–2011Based in Billund, DK· patent location history
2015Based in Copenhagen, DK· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
GLYCOZYM APS152002–2009
CLAUSEN HENRIKself112010–2017
BIOMEMBRANE INST101989–1998
VELICO MEDICAL INC92010–2015
LEGO AS52010–2011
Locations
LocationPatentsSpan
Holte, DK471994–2021
Seattle, Washington, US81989–1998
Billund, DK52010–2011
Copenhagen, DK12015
Hoite, DK12008